Pharmacological management of Cushing's syndrome: an update.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Arquivos brasileiros de endocrinologia e metabologia

• Publication date

  2007-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1590/S0004-27302007000800020PMID 18209872
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Dopamine receptor expression and function in corticotroph ectopic tumors.

  2007cited by this paper
• Ineffectiveness of rosiglitazone therapy in Nelson's syndrome.

  2007cited by this paper
• Effect of protracted treatment with rosiglitazone, a PPARγ agonist, in patients with Cushing's disease

  2006cited by this paper
• Retinoic acid as a novel medical therapy for Cushing's disease in dogs.

  2006cited by this paper
• Clinical and biochemical stabilization of Nelson’s syndrome with long-term low-dose cabergoline treatment

  2006cited by this paper
• Cortisol, aldosterone, cortisol precursor, androgen and endogenous ACTH concentrations in dogs with pituitary-dependant hyperadrenocorticism treated with trilostane.

  2006cited by this paper
• [Use of cabergoline in persisting Cushing's disease].

  2006cited by this paper
• The PPAR‐gamma activator rosiglitazone fails to lower plasma ACTH levels in patients with Nelson's syndrome

  2006cited by this paper
• Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells.

  2005cited by this paper
• Aberrant Expression of Hormone Receptors in Adrenal Cushing's Syndrome

  2005cited by this paper
• Utilisation de la cabergoline dans la maladie de Cushing non contrôlée

  2005cited by this paper
• The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5.

  2005cited by this paper
• Cabergoline plus lanreotide for ectopic Cushing's syndrome.

  2005cited by this paper
• Pre‐operative medical therapy with rosiglitazone in two patients with newly diagnosed pituitary‐dependent Cushing's syndrome

  2005cited by this paper
• Effect of pioglitazone on adrenocorticotropic hormone and cortisol secretion in Cushing's disease.

  2005cited by this paper
• Nelson’s Syndrome: Complete Remission with Cabergoline but Not with Bromocriptine or Cyproheptadine Treatment

  2004cited by this paper
• Effect of cabergoline treatment on Cushing’s disease caused by aberrant adrenocorticotropin-secreting macroadenoma

  2004cited by this paper
• Effects of chronic administration of PPAR-gamma ligand rosiglitazone in Cushing's disease.

  2004cited by this paper
• New insights on SOM230, a universal somatostatin receptor ligand.

  2003cited by this paper
• Opportunities in somatostatin research: biological, chemical and therapeutic aspects

  2003cited by this paper
• A novel somatostatin mimic with broad somatotropin release inhibitory factor receptor binding and superior therapeutic potential.

  2003cited by this paper
• The Medical Management of Cushing's Syndrome

  2002cited by this paper
• Somatostatin Receptor Subtypes 2 and 5 Inhibit Corticotropin-Releasing Hormone-Stimulated Adrenocorticotropin Secretion from AtT-20 Cells

  2002cited by this paper
• Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas.

  2002cited by this paper
• Acute promyelocytic leukemia: evolving therapeutic strategies.

  2002cited by this paper
• SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile.

  2002cited by this paper
• Macroprolactinoma associated with Cushing’s disease, successfully treated with cabergoline

  2002cited by this paper
• Functional PPAR-γ receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas

  2002cited by this paper
• The differential diagnosis of Cushing's syndrome.

  2001cited by this paper
• Successful long-term treatment of refractory Cushing's disease with high-dose mifepristone (RU 486).

  2001cited by this paper
• Retinoic acid prevents experimental Cushing syndrome.

  2001cited by this paper
• Adrenal cortical carcinoma

  2001cited by this paper
• Use of a parenteral propylene glycol-containing etomidate preparation for the long-term management of ectopic Cushing's syndrome.

  2001cited by this paper
• Fatal Liver Failure due to Ketoconazole Treatment of a Girl with Cushing's Syndrome

  2001cited by this paper
• Effect of the Serotonin Antagonists Ritanserin and Ketanserin in Cushing's Disease

  2000cited by this paper
• Medical therapy for Cushing's disease.

  1999cited by this paper
• Regulation of mouse somatostatin receptor type 2 gene expression by glucocorticoids

  1999cited by this paper
• Emergency and prolonged use of intravenous etomidate to control hypercortisolemia in a patient with Cushing's syndrome and peritonitis.

  1998cited by this paper
• Cell specific expression of the sst2A and sst5 somatostatin receptors in the rat anterior pituitary.

  1998cited by this paper
• Alternative promoter usage and tissue specific expression of the mouse somatostatin receptor 2 gene

  1998cited by this paper
• Cell Specific Expression of the SST2A and SST5 Somatostatin Receptors in the Rat Anterior Pituitary.

  1998cited by this paper
• Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation.

  1997cited by this paper
• Failure of long-term therapy with sodium valproate in Cushing’s disease

  1997cited by this paper
• Cortisol secretory patterns in Cushing's disease and response to cyproheptadine treatment.

  1996cited by this paper
• Mifepristone: treatment of Cushing's syndrome.

  1996cited by this paper
• Cyproheptadine treatment in Cushing’s disease

  1996cited by this paper
• Additive effect of ketoconazole and octreotide in the treatment of severe adrenocorticotropin-dependent hypercortisolism.

  1996cited by this paper
• Widespread distribution of somatostatin receptor messenger ribonucleic acids in rat pituitary.

  1995cited by this paper
• Expression of mRNA for somatostatin receptor (sstr) types 2 and 5 in individual rat pituitary cells. A double labeling in situ hybridization analysis.

  1995cited by this paper
• Octreotide exerts different effects in vivo and in vitro in Cushing's disease.

  1994cited by this paper
• Long-term treatment of Nelson’s syndrome by octreotide: A case report

  1994cited by this paper
• Estradiol stimulates cortisol production by adrenal cells in estrogen-dependent primary adrenocortical nodular dysplasia.

  1993cited by this paper
• The relationship between cortisol production rate and serial serum Cortisol estimation in patients on medical therapy for Cushing's syndrome

  1993cited by this paper
• The medical treatment of Cushing's syndrome.

  1993cited by this paper
• Different inhibitory effect of etomidate and ketoconazole on the human adrenal steroid biosynthesis

  1993cited by this paper
• Beneficial effects of high daily dose bromocriptine treatment in Cushing's disease.

  1992cited by this paper
• Potential therapeutic effects of ritanserin in Cushing's disease.

  1992cited by this paper
• Possible mechanism and treatment of o,p'DDD-induced hypercholesterolaemia.

  1992cited by this paper
• Mitotane increases the blood levels of hormone-binding proteins.

  1991cited by this paper
• The steroid hormone antagonist RU486. Mechanism at the cellular level and clinical applications.

  1991cited by this paper
• Short and long‐term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome

  1991cited by this paper
• Effect of Sandostatin on CRF-Stimulated Secretion of ACTH, β-Lipotropin and β-Endorphin

  1991cited by this paper
• Ketoconazole treatment in Cushing's syndrome: experience in 34 patients

  1991cited by this paper
• Prolonged bleeding time due to mitotane therapy.

  1991cited by this paper
• Ketoconazole-induced fulminant hepatitis necessitating liver transplantation.

  1991cited by this paper
• Failure of somatostatin and octreotide to acutely affect the hypothalamic-pituitary-adrenal function in patients with corticotropin hypersecretion

  1990cited by this paper
• Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy.

  1990cited by this paper
• THE EFFECT OF CYPROHEPTADINE AND/OR BROMOCRIPTINE ON PLASMA ACTH LEVELS IN PATIENTS CURED OF CUSHING'S DISEASE BY BILATERAL ADRENALECTOMY

  1990cited by this paper
• The effect of the long-acting somatostatin analogue SMS 201-995 on ACTH secretion in Nelson's syndrome and Cushing's disease.

  1989cited by this paper
• Inhibition of human adrenal androgen secretion by ketoconazole

  1989cited by this paper
• The protracted effect of o,p'-DDD in Cushing's disease and its impact on adrenal morphogenesis of young human embryo.

  1989cited by this paper
• HEPATIC MICROSOMAL ENZYME INDUCTION AND ADRENAL CRISIS DUE TO o,p’DDD THERAPY FOR METASTATIC ADRENOCORTICAL CARCINOMA

  1989cited by this paper
• THE PITUITARY‐ADRENAL RESPONSE TO CRF‐41 IS UNALTERED BY INTRAVENOUS SOMATOSTATIN IN NORMAL SUBJECTS

  1989cited by this paper
• Suppression of ectopic adrenocorticotropin secretion by the long-acting somatostatin analog octreotide.

  1989cited by this paper
• Bromocriptine-responsive Cushing's disease associated with anterior pituitary corticotroph hyperplasia or normal pituitary gland.

  1989cited by this paper
• The role of somatostatin in the regulation of anterior pituitary hormone secretion and the use of its analogs in the treatment of human pituitary tumors.

  1988cited by this paper
• THE COMBINED USE OF SODIUM VALPROATE AND METYRAPONE IN THE TREATMENT OF CUSHING'S SYNDROME

  1988cited by this paper
• Aminoglutethimide and ketoconazole: historical perspectives and future prospects.

  1988cited by this paper
• Nonhypnotic low-dose etomidate for rapid correction of hypercortisolaemia in cushing's syndrome

  1988cited by this paper
• Cholesterol metabolism during ketoconazole treatment in man.

  1988cited by this paper
• Primary adrenocortical micronodular adenomatosis causing Cushing's syndrome. Effects of ketoconazole on steroid production and in vitro performance of adrenal cells.

  1986cited by this paper
• The endocrine effects of ketoconazole

  1986cited by this paper
• Ketoconazole-associated hepatic injury. A clinicopathological study of 55 cases.

  1986cited by this paper
• Pituitary-adrenal response to the antiglucocorticoid action of RU 486 in Cushing's syndrome.

  1986cited by this paper
• Increased adrenocorticotropin, cortisol, and arginine vasopressin secretion in primates after the antiglucocorticoid steroid RU 486: dose response relationships.

  1985cited by this paper
• Successful treatment of Cushing's syndrome with the glucocorticoid antagonist RU 486.

  1985cited by this paper
• Ketoconazole blocks cortisol secretion in man by inhibition of adrenal 11β-hydroxylase

  1985cited by this paper
• Pregnancy complicated by Cushing's syndrome: potential hazard of metyrapone therapy. Case report

  1985cited by this paper
• Ketoconazole therapy in Cushing's disease.

  1985cited by this paper
• Release of pro-opiomelanocortin-derived peptides from the pars intermedia and pars distalis of the rat pituitary: effect of corticotrophin-releasing factor and somatostatin.

  1985cited by this paper
• Effect of hypothalamic neuropeptides on corticotrophin release from quarters of rat anterior pituitary gland in vitro.

  1984cited by this paper
• Hepatic injury associated with ketoconazole therapy. Analysis of 33 cases.

  1984cited by this paper
• Sodium valproate and metyrapone for pituitary-dependent Cushing's disease.

  1984cited by this paper
• Effects of corticotropin-releasing factor and other materials on adrenocorticotropin secretion from pituitary glands of patients with Cushing's disease in vitro.

  1984cited by this paper
• Central nervous system regulation of adrenocorticotropin secretion: role of somatostatins.

  1984cited by this paper
• Influence of sedation on mortality in critically ill multiple trauma patients.

  1983cited by this paper
• Effects of cyproheptadine, reserpine, and synthetic corticotropin-releasing factor on pituitary glands from patients with Cushing's disease.

  1983cited by this paper
• EFFECT OF BROMOCRIPTINE IN PITUITARY‐DEPENDENT CUSHING'S SYNDROME

  1983cited by this paper
• EXPERIENCE WITH TRILOSTANE IN THE TREATMENT OF CUSHING'S SYNDROME

  1983cited by this paper
• Long-term etomidate and adrenocortical suppression.

  1983cited by this paper

• Drug development and potential targets for Cushing's syndrome.

  2024cites this paper
• The effect of adjuvant mitotane therapy of the adrenocortical carcinoma on the endometrium and its clinical consequences in menstruating women. Literature review and authors' own experiences.

  2024cites this paper
• Critical illness-related corticosteroid insufficiency (CIRCI) - an overview of pathogenesis, clinical presentation and management

  2024cites this paper
• Autophagy and Pituitary Adenoma.

  2020cites this paper
• Lead optimization of highly potent and selective CYP11B1 inhibitors for the treatment of Cushing’s syndrome and chronic wounds

  2017cites this paper
• Pituitary adenomas: an overview of clinical features, diagnosis and treatment

  2017cites this paper
• Efeito da cabergolina no adenoma hipofisário clinicamente não funcionante e correlação dos polimorfismos do gene do receptor do glicocorticoide e da proteína AIP nos corticotropinomas

  2017cites this paper
• Symptomatic Cushing’s syndrome and hyperandrogenemia in a steroid cell ovarian neoplasm: a case report

  2016influential citation
• Inhibitors of 11β-Hydroxylase (CYP11B1) for Treating Diseases Related to Excess Cortisol.

  2016cites this paper
• Clinical use of pasireotide for Cushing’s disease in adults

  2015cites this paper
• Managing Cushing’s disease: the state of the art

  2014cites this paper
• Molecular basis of pharmacological therapy in Cushing’s disease

  2014influential citation
• Medical management of Cushing’s syndrome

  2013cites this paper
• Managing hyperglycemia in patients with Cushing’s disease treated with pasireotide: medical expert recommendations

  2013cites this paper
• The management of Cushing's disease - from investigation to treatment.

  2013cites this paper
• Medical Management of Pituitary Adenomas

  2013cites this paper
• Cushing’s disease: current trends in treatment

  2013cites this paper
• Cushing's syndrome: development of highly potent and selective CYP11B1 inhibitors of the (pyridylmethyl)pyridine type.

  2013cites this paper
• Mifepristone for Management of Cushing's Syndrome

  2013cites this paper
• A reappraisal of the medical therapy with steroidogenesis inhibitors in Cushing's syndrome

  2012cites this paper
• The Therapy of Cushing’s Disease in Adults and Children: An Update

  2012cites this paper
• Medical suppression of hypercortisolemia in Cushing’s syndrome with particular consideration of etomidate

  2012cites this paper
• Effectiveness of chronic treatment with ketoconazole in a patient with diabetic Cushing's disease resistant to surgery.

  2011cites this paper
• Review of use of drugs for conditions not included in product characteristics.

  2011cites this paper
• Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing's syndrome.

  2011cites this paper
• Revisión sobre el uso de medicamentos en condiciones no incluidas en su ficha técnica

  2011cites this paper
• Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing’s disease

  2010influential citation
• Papel da via lkaros-FGFR4 na evolução pós-cirúrgica dos pacientes com doença de Cushing

  2010cites this paper
• [Treatment of pituitary adenomas].

  2009cites this paper
• [The medical management of Cushing's syndrome].

  2009cites this paper
• Cortisol and Glucose: Reliable indicators of fish stress?

  2009cites this paper
• Medical Therapy for Cushing’s Disease – Past and Future Modes of Treatment

  2008cites this paper